InvestmentPitch Media Video Discusses Rakovina Therapeutics’ Partnership with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

Vancouver, British Columbia–(Newsfile Corp. – November 17, 2021) – Rakovina Therapeutics Inc. (TSXV: RKV), a biopharmaceutical company committed to advancing novel cancer therapies based on novel DNA damage response technologies, has been selected to participate in a three-year research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All. The $975,000 or CDN$1,297,000 research program is focused on developing new treatments for Ewing’s sarcoma, an aggressive cancer of bone and soft tissue in children and young adults.

For more information, watch InvestmentPitch Media’s “video” which provides additional information about this news and the company. If this link is not enabled, go to and type “Rakovina” in the search box.

Can’t watch this video? Visit:

Martha’s Better Ewing Sarcoma Treatment (BEST) Grant for All is a St. Baldrick’s grant named in honor of a 19-year-old girl who has battled the disease for more than 6 years after being first diagnosed with Ewing’s sarcoma in 2015. received. 13 years. Martha was happy to have her name linked to the scholarship, but insisted on the “for everyone” to acknowledge the many other children diagnosed with Ewing sarcoma each year. Having faced numerous relapses over the years, Martha is fearless and continues her battle with Ewing’s sarcoma. Martha continues to place her trust in the cancer research community and plans to enroll in a clinical trial at Boston Children’s Hospital in December 2021.

Prof. dr. Mads Daugaard, president of Rakovina Therapeutics and Chief Scientific Officer, is a principal investigator on the project along with Prof. Poul Sorensen at the University of British Columbia. Rakovina Therapeutics recently presented preclinical data at peer-reviewed scientific meetings demonstrating the potential of Rakovina Therapeutics’ kt-3000 series drug candidates against treatment-resistant cancer cell lines, including Ewing’s sarcoma.

Story continues

Prof. dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina, said: “Our data demonstrate that kt-3000 series compounds are equivalent or more effective against Ewing sarcoma cells in vitro compared to FDA-approved PARP inhibitors, which are Currently, there are no FDA-approved treatments for recurrent Ewing sarcoma, which is largely resistant to conventional therapies and immunotherapy; new treatment strategies are desperately needed.”

Kathleen Ruddy, CEO, St. Baldrick’s Foundation, added: “This incredibly generous large donation has enabled us to partner with the University of British Columbia to seek and fund new research on Ewing’s sarcoma. Recently reported data from Rakovina Therapeutics shows early promise as a potential treatment for Ewing sarcoma and we are pleased to welcome the company to this important project, which supports groundbreaking research in the hopes of finding new treatments for this deadly disease. Thousands of donors and volunteers have contributed the St. Baldrick’s Foundation establishes the largest non-governmental funder of childhood cancer research grants Our volunteers and scientists work tirelessly to ensure that current and future children diagnosed with cancer have access to the best treatments and that tomorrow’s treatments have less toxic effects in the long run will have and.”

Jeffrey Bacha, executive chairman of Rakovina, commented: “Rakovina Therapeutics is pleased to be an industry partner in the St. Baldrick’s Foundation mission to support the most promising research to find treatments for childhood cancer and help survivors live long, healthy lives.” We will strive to bring drug candidates quickly to the clinical arena as preclinical work the IND allows.”

Rakovina Therapeutics was founded in 2020 to develop novel cancer treatments based on novel DNA damage response technologies. The company has established a pipeline of DNA damage response inhibitors with the goal of bringing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapies from Health Canada, the U.S. Food and Drug Administration and comparable international regulatory bodies. .

The shares, which traded on April 1, are currently trading at $0.23. For more information, visit the company’s website, contact David Hyman, CFO, at 403-613-1453 or by email at For investor relations, please email

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which along with its extensive distribution positions a company’s story above the thousands of companies seeking exposure and funding from the financial community. The company specializes in producing short videos based on key press releases, research reports, and other content of interest to investors.

InvestmentsPitch Media
Barry Morgan, CFO

To view the source version of this press release, visit

Comments are closed.